Dr. Garassino on the Clinical Implications of Tepotinib in METex14-Altered NSCLC
September 24th 2021Marina Chiara Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the clinical implications of the phase 2 VISION trial evaluating patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.
Early Relapse Confers Worse Prognosis After Transplant, Calling for Novel Options in High-Risk MCL
June 23rd 2021Peter Riedell, MD, discusses the rationale for a study in mantle cell lymphoma, the clinical implications of the findings, and unanswered questions that future research efforts should aim to answer.
Garassino Highlights What’s In Store for Lung Cancer
June 21st 2021Patients with lung cancer were identified as an at-risk group for developing severe complications as a result of SARS-CoV-2 infection, and thoracic oncologists were fast to respond with the establishment of the Thoracic Cancers International COVID-19 Collaboration.
Talking Tumors: Treating With Immunotherapy and Targeted Therapy in Lung Cancer
April 20th 2020Jyoti D. Patel, MD and Lawrence E. Feldman, MD, discuss second-line therapy in extensive-stage small cell lung cancer and the need for consolidative radiation, as well as the optimal sequence of therapy for a patient with non–small cell lung cancer who harbors a MET exon 14 mutation.